Translational Medicine Lead, Precision Medicine, Early Clinical Development Pfizer Inc. Groton, Connecticut
Implementing an end-to-end biomarker strategy during drug development accelerates data-driven decision making and increases the likelihood of clinical success. This lecture comprises 3 main topics including i) an overview of biomarker use in drug development, ii) a case study which illustrates the biomarker development pipeline and iii) recent advances in the biomarker field which enable a patient-centric approach to clinical trial design.
Learning Objectives:
To identify strategic opportunities for biomarker implementation throughout the drug development pipeline
To understand the workflow involved in identifying, characterizing, validating, and qualifying a novel biomarker
To gain familiarity with recent advances in the biomarker field which enable a patient-centric approach to clinical trial design